Similarly, mutations in the IDH1/2-TET2-WT1 network, which collectively appear in 30-50% of AML cases [20,81,131], also present an apparent hypermethylated phenotype as a consequence of deficient TET2 activity [82,135]. This evidence concerns the gene TET2 and acute myeloid leukemia.